NEWS

19 juli 2021
19 juli 2021

Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Do you like it?
Read more
18 december 2019
18 december 2019

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

Do you like it?
Read more
3 december 2019
3 december 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

Do you like it?
Read more
Load more